Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.67 |
| ▸ | DRD2 | P14416 | 11/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.67 |
| ▸ | HTR2A | P28223 | 4/20 | 0.67 |
| ▸ | DRD4 | P21917 | 3/20 | 0.67 |
| ▸ | DRD3 | P35462 | 3/20 | 0.67 |
| ▸ | HTR7 | P34969 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906289 | 0.87 | HTR1A (0.71) | HTR1ADRD2OPRM1OPRK1HTR2A | |
| SCHEMBL6908792 | 0.85 | HTR1A (0.73) | HTR1ADRD2OPRM1OPRK1HTR2A | |
| SCHEMBL6908250 | 0.84 | HTR1A (0.69) | HTR1ADRD2OPRM1OPRK1HTR2A | |
| Spiroxatrine SCHEMBL1255303 | 0.81 | DRD2 (1.00) | HTR1ADRD2OPRM1OPRK1HTR2A | |
| SCHEMBL6991007 | 0.79 | HTR1A (0.70) | HTR1ADRD2OPRM1OPRK1HTR2A | |
| SCHEMBL6773488 | 0.77 | ADRA2A (0.50) | HTR1ADRD2DRD4DRD3CYP3A4 | |
| SCHEMBL9386414 | 0.76 | OPRL1 (0.66) | HTR1ADRD2OPRM1OPRK1HTR2A | |
| SCHEMBL6777242 | 0.74 | HTR1A (0.42) | HTR1ADRD2HTR2ADRD4DRD3 | |
| SCHEMBL6782983 | 0.73 | HTR1A (0.58) | HTR1ADRD2DRD4DRD3MEN1 | |
| SCHEMBL6772982 | 0.73 | DRD2 (0.60) | HTR1ADRD2OPRM1OPRK1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815448-B2 | FOR THERAPY OF OGNITIVE DEFICITS DUE TO AGING, STROKE, HEAD TRAUMA, ALZHEIMER'S DISEASE OR OTHER NEURODEGENERATIVE DISEASES, OR SCHIZOPHRENIA; ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA | WYETH | 2004-11-09 | — | — | US | claimed |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2002-12-19 | — | — | US | claimed |
| WO-2002090362-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-14 | — | — | WO | claimed |
| US-6815448-B2 | FOR THERAPY OF OGNITIVE DEFICITS DUE TO AGING, STROKE, HEAD TRAUMA, ALZHEIMER'S DISEASE OR OTHER NEURODEGENERATIVE DISEASES, OR SCHIZOPHRENIA; ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA | WYETH | 2004-11-09 | — | — | US | disclosed |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002090362-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | HTR1A, HTR5A, HTR1D | HTR1A 1/4885DRD2 185/4885OPRM1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.